4D Molecular Therapeutics (FDMT) EPS (Weighted Average and Diluted) (2021 - 2026)
4D Molecular Therapeutics (FDMT) reported EPS (Weighted Average and Diluted) of -$1.01 for Q1 2026, down 17.44% year-over-year from -$1.22 in Q1 2025, and down 334.88% quarter-over-quarter from $0.43 in Q4 2025.
4D Molecular Therapeutics (FDMT) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.01 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.01, down 17.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.57 (up 19.18% YoY), and the FY2025 annual result was -$2.42, up 18.79% from the prior year.
- EPS (Weighted Average and Diluted) declined to -$1.01 in Q1 2026 per FDMT's latest filing, from $0.43 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.43 in Q4 2025 and troughed at -$1.01 in Q3 2025.
- A 5-year average of -$0.73 and a median of -$0.82 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) slumped 229.17% in 2024, then surged 147.78% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.84 in 2022, then advanced by 8.33% to -$0.77 in 2023, then slipped by 16.88% to -$0.9 in 2024, then jumped by 147.78% to $0.43 in 2025, then plunged by 334.88% to -$1.01 in 2026.
- Business Quant data shows FDMT's EPS (Weighted Average and Diluted) at -$1.01 in Q1 2026, $0.43 in Q4 2025, and -$1.01 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -1.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.01 |
| Dec 31, 2025 | 0.43 |
| Sep 30, 2025 | -1.01 |
| Jun 30, 2025 | -0.98 |
| Mar 31, 2025 | -0.86 |
| Dec 31, 2024 | -0.90 |
| Sep 30, 2024 | -0.79 |
| Jun 30, 2024 | -0.63 |
| Mar 31, 2024 | -0.66 |
| Dec 31, 2023 | -0.77 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.77 |
| Mar 31, 2023 | -0.88 |
| Dec 31, 2022 | -0.84 |
| Sep 30, 2022 | -0.79 |
| Jun 30, 2022 | -0.87 |
| Mar 31, 2022 | -0.82 |
| Dec 31, 2021 | -0.85 |
| Sep 30, 2021 | -0.82 |
| Jun 30, 2021 | -0.28 |